Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint
has demonstrated unprecedented clinical efficacy in the treatment of advanced cancers …

PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-
PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1–PD …

Mutations of the TP53 gene and dysregulation of the TP53 pathway are important in the
pathogenesis of many human cancers, including lymphomas. Tumor suppression by p53 …

Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …

PURPOSE: Approximately 5% of diffuse large B-cell lymphomas (DLBCLs) are double-hit
lymphomas (DHLs) with translocations of both MYC and BCL2. DHLs are characterized by …

Purpose Breast implant–associated anaplastic large-cell lymphoma (ALCL) is a recently
described clinicopathologic entity that usually presents as an effusion-associated fibrous …

TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-
cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine …

Gene expression profiling (GEP) has stratified diffuse large B-cell lymphoma (DLBCL) into
molecular subgroups that correspond to different stages of lymphocyte development …

Richter syndrome (RS) represents the development of diffuse large B-cell lymphoma in the
context of chronic lymphocytic leukemia. The scarcity of biologic information about RS has …

CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of
classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma …